WAVE Life Sciences (NASDAQ:WVE – Get Free Report) had its price target cut by Citigroup from $19.00 to $15.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup‘s price target suggests a potential upside of 379.23% from the stock’s current price.
WVE has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of WAVE Life Sciences in a report on Thursday, October 15th. UBS Group assumed coverage on WAVE Life Sciences in a research report on Thursday, October 15th. They issued a “buy” rating and a $11.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on shares of WAVE Life Sciences in a research note on Wednesday, September 23rd. They set a “neutral” rating on the stock. Zacks Research cut WAVE Life Sciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Finally, Ladenburg Thalmann & Co. Inc. began coverage on shares of WAVE Life Sciences in a report on Thursday, October 1st. They issued a “buy” rating and a $10.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $20.44.
Read Our Latest Report on WAVE Life Sciences
WAVE Life Sciences Stock Down 0.6%
WAVE Life Sciences (NASDAQ:WVE – Get Free Report) last issued its quarterly earnings data on Tuesday, October 27th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.03. The firm had revenue of $13.16 million during the quarter, compared to the consensus estimate of $4.51 million. WAVE Life Sciences had a negative net margin of 296.86% and a negative return on equity of 44.66%. On average, analysts anticipate that WAVE Life Sciences will post -1.08 earnings per share for the current year.
Institutional Investors Weigh In On WAVE Life Sciences
Several hedge funds have recently added to or reduced their stakes in the company. AlphaCentric Advisors LLC increased its holdings in shares of WAVE Life Sciences by 5.7% in the 1st quarter. AlphaCentric Advisors LLC now owns 29,175 shares of the company’s stock valued at $212,000 after acquiring an additional 1,585 shares during the last quarter. First Trust Advisors LP lifted its position in WAVE Life Sciences by 15.7% during the 1st quarter. First Trust Advisors LP now owns 13,518 shares of the company’s stock worth $98,000 after acquiring an additional 1,830 shares during the period. Arizona State Retirement System grew its position in WAVE Life Sciences by 17.1% in the 2nd quarter. Arizona State Retirement System now owns 35,826 shares of the company’s stock valued at $208,000 after buying an additional 5,228 shares during the last quarter. Bessemer Group Inc. increased its stake in WAVE Life Sciences by 118.4% in the 3rd quarter. Bessemer Group Inc. now owns 15,550 shares of the company’s stock valued at $58,000 after buying an additional 8,430 shares during the period. Finally, Quantinno Capital Management LP raised its holdings in WAVE Life Sciences by 23.0% during the first quarter. Quantinno Capital Management LP now owns 47,885 shares of the company’s stock worth $347,000 after purchasing an additional 8,960 shares in the last quarter. Institutional investors own 89.73% of the company’s stock.
WAVE Life Sciences Company Profile
WAVE Life Sciences Ltd. is a biotechnology company developing RNA-based medicines for genetically defined diseases. Founded in 2012, the company is headquartered in Cambridge, Massachusetts, and uses its oligonucleotide chemistry and drug-design capabilities to develop treatments intended to alter or regulate gene expression. Its research includes antisense oligonucleotide therapies and RNA-editing approaches. Programs have targeted conditions such as Huntington’s disease and alpha-1 antitrypsin deficiency, with the latter exploring RNA editing to address a disease-causing genetic variant.
Recommended Stories
- Five stocks we like better than WAVE Life Sciences
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for WAVE Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
